Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
ART of SABR: A Randomized Phase II Trial of Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer: Two Versus Five Fractions
Sponsor: Mayo Clinic
Listed as NCT06325046, this NA trial focuses on Localized Prostate Adenocarcinoma and Stage I Prostate Cancer AJCC v8 and remains actively recruiting participants. Sponsored by Mayo Clinic, it has been updated 10 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Recruiting NA
-
Mar 2025 — Nov 2025 [monthly]
Recruiting NA
-
Feb 2025 — Mar 2025 [monthly]
Recruiting NA
-
Nov 2024 — Feb 2025 [monthly]
Recruiting NA
-
Oct 2024 — Nov 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting NA
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting NA
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting NA
-
Apr 2024 — May 2024 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .